Floatz logo

Recombinant Interleukin-12

Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2CCC
Carboplatin
National Cancer Institute (NCI)
Phase 1CC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 1CC
Alvespimycin
National Cancer Institute (NCI)
Phase 1CC
Abi-007
National Cancer Institute (NCI)
Phase 1CC
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI
Stanford University
Phase 1CC
Gefetinib
National Cancer Institute (NCI)
N/ANR

Same molecule, other indications

Recombinant Interleukin-12 is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
64 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →